Company profile for EnteraBio Ltd

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract.Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceu...
Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract.Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Kiryat Hadassah Minrav Building, 5th Floor Po Box 12117 Jerusalem 9122002 Isra...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/18/3189917/0/en/Entera-Bio-to-Participate-in-the-8th-Annual-Evercore-ISI-Healthcare-Conference.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188598/0/en/Entera-Bio-Announces-Third-Quarter-2025-Financial-Results-and-Business-Updates.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/10/23/3172057/0/en/Entera-Bio-Presents-Positive-New-Clinical-Data-from-EB613-Phase-2-Trial-Demonstrating-Significant-Bone-Density-Improvements-in-Early-Postmenopausal-Women.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3167926/0/en/Entera-Bio-to-Present-New-Clinical-Data-from-Phase-2-Trial-of-EB613-at-the-2025-North-American-Menopause-Society-NAMS-Annual-Meeting.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/09/15/3150045/0/en/Entera-Bio-Reports-Positive-PK-Data-for-First-in-Class-Oral-GLP-2-Tablet-Treatment-for-Patients-with-Short-Bowel-Syndrome-at-the-2025-ESPEN-Congress.html

GLOBENEWSWIRE
15 Sep 2025

https://www.globenewswire.com/news-release/2025/09/08/3146096/0/en/Entera-Bio-Presents-Positive-Effects-of-EB613-on-Both-Trabecular-and-Cortical-Bone-in-Postmenopausal-Women-with-Osteoporosis-at-ASBMR-2025.html

GLOBENEWSWIRE
08 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty